Shillong Herald

Obesity Therapeutic Pipeline Analysis, 2023 Updates | Insights into the Latest FDA, EMA, and PMDA Approvals, Breakthroughs, Clinical and Non-Clinical Trials, Emerging Therapies

 Breaking News
  • No posts were found

Obesity Therapeutic Pipeline Analysis, 2023 Updates | Insights into the Latest FDA, EMA, and PMDA Approvals, Breakthroughs, Clinical and Non-Clinical Trials, Emerging Therapies

May 11
19:48 2023
Obesity Therapeutic Pipeline Analysis, 2023 Updates  | Insights into the Latest FDA, EMA, and PMDA Approvals, Breakthroughs, Clinical and Non-Clinical Trials, Emerging Therapies
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Obesity pipeline constitutes 100+ key companies continuously working towards developing 130+ Obesity treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Obesity Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Obesity Pipeline Insight, 2023 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Obesity Market.

 

Some of the key takeaways from the Obesity Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Obesity treatment therapies with a considerable amount of success over the years. 
  • Obesity companies working in the treatment market are Carmot Therapeutics, Eli Lilly and Company, Oral Novo Nordisk, Tonix Pharmaceuticals, BioRestorative Therapies, SCOHIA PHARMA, Click Therapeutics, Hanmi Pharmaceuticals, Pharmatech, Caliway Biopharmaceutics, Nano Precision Medical, Bukwang Pharmaceutical, Yuhan, Novo Nordisk, Sciwind Biosciences, Empros Pharma, and others, are developing therapies for the Obesity treatment 
  • Emerging Obesity therapies such as – CT-868, Tirzepatide, Semaglutide, TNX-2900, Thermostem, SCO-267, CT-181, HM15136, DD03 D&D, CBW-520, NPM 139, BK-1701, YH34160, NNC0480-0389, XW003, EMP-16, and others are expected to have a significant impact on the Obesity market in the coming years.   
  • In October 2022, The US Food and Drug Administration (FDA) has granted FastTrack Designation (FTD) for the examination of tirzepatide for the treatment of individuals with obesity or overweight with weight-related comorbidities, according to an announcement from Eli Lilly & Company
  • In February 2022, To assess the effectiveness, safety, and tolerability of CT-868 given for 26 weeks to overweight and obese participants with Type 2 diabetes mellitus, Carmot Therapeutics started a randomised, double-blind, placebo-controlled, parallel-group, multi-center trial
  • In July 2021, In order to promote research, develop, and commercialise small molecule drugs that are aimed against the GPR75 target and have the potential to treat obesity and associated co-morbidities, AstraZeneca partnered with Regeneron
  • In June 2021, IBI362, a dual agonist for the glucagon-like peptide 1 receptor (GLP-1R) and glucagon receptor (GCGR), has successfully dosed its first subject in a Phase II clinical trial (NCT04904913) in China, according to an announcement from Innovent Biologics
  • In April 2021, Two Phase II studies of the GLP-1/glucagon dual agonist BI 456906 for adults with non-alcoholic steatohepatitis (NASH) and obesity were recently disclosed by Boehringer Ingelheim and Zealand Pharma

 

Obesity Overview

Obesity is understood to be a chronic or non-communicable condition that affects, along with overweight, and is largely related with excess adiposity or body fatness, which can express physiologically and not just with regard to physical size.

 

Get a Free Sample PDF Report to know more about Obesity Pipeline Therapeutic Assessment-

https://www.delveinsight.com/sample-request/obesity-pipeline-insight

 

Emerging Obesity Drugs Under Different Phases of Clinical Development Include:

  • CT-868: Carmot Therapeutics
  • Tirzepatide: Eli Lilly and Company
  • Tesomet: Saniona
  • RZL-012: Raziel Therapeutics
  • EMP16: Empros Pharma
  • ZP 8396: Zealand Pharma
  • ERX-1000: ERX Pharmaceuticals
  • Semaglutide: Oral Novo Nordisk
  • TNX-2900: Tonix Pharmaceuticals
  • Thermostem: BioRestorative Therapies
  • SCO-267: SCOHIA PHARMA
  • CT-181: Click Therapeutics
  • HM15136: Hanmi Pharmaceuticals
  • DD03 D&D: Pharmatech
  • CBW-520: Caliway Biopharmaceutics
  • NPM 139: Nano Precision Medical
  • BK-1701: Bukwang Pharmaceutical
  • YH34160: Yuhan
  • NNC0480-0389: Novo Nordisk
  • XW003: Sciwind Biosciences
  • EMP-16: Empros Pharma

 

Route of Administration

Obesity pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical

 

Molecule Type

Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy 

 

Obesity Pipeline Therapeutics Assessment

  • Obesity Assessment by Product Type
  • Obesity By Stage and Product Type
  • Obesity Assessment by Route of Administration
  • Obesity By Stage and Route of Administration
  • Obesity Assessment by Molecule Type
  • Obesity by Stage and Molecule Type

 

DelveInsight’s Obesity Report covers around 130+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Obesity product details are provided in the report. Download the Obesity pipeline report to learn more about the emerging Obesity therapies

 

Some of the key companies in the Obesity Therapeutics Market include:

Key companies developing therapies for Obesity are – Novo Nordisk A/S, Eli Lilly and Company, Novartis International AG, Johnson & Johnson, AstraZeneca PLC, Roche Holding AG, Pfizer Inc., Merck & Co., Inc., Sanofi, Eisai Co., Ltd., Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, Bristol Myers Squibb, Orexigen Therapeutics, Inc., Arena Pharmaceuticals, Inc., Vivus Inc., Zafgen Inc., NantKwest Inc., Rhythm Pharmaceuticals, Inc., EnteroMedics Inc., Gelesis, Inc., Allergan PLC, Medifast, Inc., Obalon Therapeutics, Inc., Herbalife Nutrition Ltd., GNC Holdings, Inc., Nutrisystem, Inc., WW International, Inc. (formerly Weight Watchers), Slimming World, and others.

 

Obesity Pipeline Analysis:

The Obesity pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Obesity with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Obesity Treatment.
  • Obesity key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Obesity Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Obesity market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Obesity drugs and therapies

 

Obesity Pipeline Market Drivers

  • Rise in prevalence of Obesity, growing Research and Development Activities to develop novel therapies to treat obesity, changing lifestyle patterns are some of the important factors that are fueling the Obesity Market.

 

Obesity Pipeline Market Barriers

  • However, challenges associated with the discovery of anti-obesity drugs, economic burden associated with obesity and other factors are creating obstacles in the Obesity Market growth.

 

Scope of Obesity Pipeline Drug Insight    

  • Coverage: Global
  • Key Obesity Companies: Carmot Therapeutics, Eli Lilly and Company, Oral Novo Nordisk, Tonix Pharmaceuticals, BioRestorative Therapies, SCOHIA PHARMA, Click Therapeutics, Hanmi Pharmaceuticals, Pharmatech, Caliway Biopharmaceutics, Nano Precision Medical, Bukwang Pharmaceutical, Yuhan, Novo Nordisk, Sciwind Biosciences, Empros Pharma, and others
  • Key Obesity Therapies: CT-868, Tirzepatide, Semaglutide, TNX-2900, Thermostem, SCO-267, CT-181, HM15136, DD03 D&D, CBW-520, NPM 139, BK-1701, YH34160, NNC0480-0389, XW003, EMP-16, and others
  • Obesity Therapeutic Assessment: Obesity current marketed and Obesity emerging therapies
  • Obesity Market Dynamics: Obesity market drivers and Obesity market barriers 

 

Request for Sample PDF Report for Obesity Pipeline Assessment and clinical trials

 

Table of Contents

1

Obesity Report Introduction

2

Obesity Executive Summary

3

Obesity Overview

4

Obesity- Analytical Perspective In-depth Commercial Assessment

5

Obesity Pipeline Therapeutics

6

Obesity Late Stage Products (Phase II/III)

7

Obesity Mid Stage Products (Phase II)

8

Obesity Early Stage Products (Phase I)

9

Obesity Preclinical Stage Products

10

Obesity Therapeutics Assessment

11

Obesity Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Obesity Key Companies

14

Obesity Key Products

15

Obesity Unmet Needs

16 

Obesity Market Drivers and Barriers

17

Obesity Future Perspectives and Conclusion

18

Obesity Analyst Views

19

Appendix

20

About DelveInsight

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

 

About DelveInsight

 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services

Related Articles

Recent Posts

Tinea Pedis Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | GlaxoSmithKline, Novartis, South End Skin Care, Taro Pharma, Medicis Global

Read Full Article